Last kr0.97 DKK
Change Today +0.01 / 1.04%
Volume 1.8M
VELO On Other Exchanges
As of 11:03 AM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

veloxis pharmaceuticals a/s (VELO) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/17/14 - kr1.07
52 Week Low
04/17/13 - kr0.41
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

veloxis pharmaceuticals a/s (VELO) Related Businessweek News

No Related Businessweek News Found

veloxis pharmaceuticals a/s (VELO) Details

Veloxis Pharmaceuticals A/S operates as a specialty pharmaceutical company. Its proprietary technology, MeltDose is used to enhance absorption and bioavailability of compounds for a range of marketed drugs. The company’s product candidate includes LCP-Tacro, which is in Phase III clinical trial product for the prevention of organ rejection in kidney transplant patients; and has completed Phase II clinical studies for patients who have undergone a liver transplant. Its products also comprises Fenoglide for the treatment of dyslipidemia in the United States market; and AtorFen, which has completed Phase II clinical studies for the treatment of dyslipidemia, as well as a diversified near and medium term pipeline with three clinical stage product candidates and various projects in preclinical development. The company was formerly known as LifeCycle Pharma A/S and changed its name to Veloxis Pharmaceuticals A/S in July 2011. Veloxis Pharmaceuticals A/S is based in Hørsholm, Denmark.

24 Employees
Last Reported Date: 03/5/14

veloxis pharmaceuticals a/s (VELO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

veloxis pharmaceuticals a/s (VELO) Key Developments

Veloxis Pharmaceuticals Proposes Amendment of Articles of Association

Veloxis Pharmaceuticals at the AGM to be held on April 9, 2014, proposed amendment of the articles of association.

U.S. FDA Accepts Veloxis Pharmaceuticals A/S's New Drug Application for Envarsus(R) for the Prevention of Organ Rejection in Kidney Transplant Patients

Veloxis Pharmaceuticals A/S announced the U.S. FDA accepted for standard review the company's New Drug Application for Envarsus(R) for the prevention of organ rejection in adult kidney transplant patients. Envarsus(R) is Veloxis' once-daily tacrolimus based on the company's proprietary MELTDOSE technology. FDA has set a target review date under the Prescription Drug User Fee Act (PDUFA) of October 30, 2014. The NDA was submitted to the FDA on 30 December, 2013. The NDA is based on two Phase III studies, 3001 and 3002, in which Envarsus demonstrated non-inferiority compared to twice daily tacrolimus (Prograf(R)) based on a composite endpoint of treatment failure at one year. The clinical program comprised 25 studies and enrolled over 1,000 patients. Envarsus is a once-daily formulation of tacrolimus that demonstrates a smoother pharmacokinetic profile and enables lower dosing to maintain therapeutic blood levels compared to twice-daily tacrolimus. Envarsus received Orphan Drug Designation by the U.S. FDA for prophylaxis of organ rejection in patients receiving allogeneic kidney transplants.

Veloxis Pharmaceuticals A/S Promotes John Weinberg to Chief Operating Officer

Veloxis Pharmaceuticals A/S announced that John Weinberg, M.D., currently chief commercial officer of Veloxis, has been promoted to chief operating officer. Dr. Weinberg, who is currently responsible for the commercial launch of Envarsus in the U.S., if approved by the Food and Drug Administration (FDA), will expand his role at the company to include additional operational responsibilities.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VELO:DC kr0.97 DKK +0.01

VELO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €8.35 EUR +0.072
Oxford Biomedica PLC 2.20 GBp 0.00
Swedish Orphan Biovitrum AB kr66.70 SEK +0.25
View Industry Companies

Industry Analysis


Industry Average

Valuation VELO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 42.0x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 33.4x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VELOXIS PHARMACEUTICALS A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at